Community Medicine
10 questionsWhich of the following is NOT one of Bradford Hill's criteria for causation?
What is the most important criterion in a causal relationship hypothesis?
What is the primary benefit of screening for diseases?
Multiphasic screening means-
What is a key benefit of Randomized Controlled Trials (RCTs) in clinical research?
Most commonly used blinding technique in epidemiological studies?
Which one of the following is NOT a utilization rate?
Which of the following statements is true regarding a combined prospective-retrospective study?
What is the definition of Population Attributable Risk?
Which study design is most effective for investigating rare adverse effects of a drug?
NEET-PG 2015 - Community Medicine NEET-PG Practice Questions and MCQs
Question 701: Which of the following is NOT one of Bradford Hill's criteria for causation?
- A. Consistency of association
- B. Specificity of association
- C. Strength of association
- D. Absence of temporal relationship (Correct Answer)
Explanation: ***Absence of temporal relationship*** - Bradford Hill's criteria include **temporality** (temporal relationship), which states that the cause must precede the effect in time. - The criterion is the **presence** of a temporal relationship, not its absence. - "Absence of temporal relationship" is therefore NOT one of Bradford Hill's criteria—it is the opposite of what the criterion requires. - This is the correct answer to this "NOT" question. *Strength of association* - This **IS** one of Bradford Hill's criteria. - It refers to the **magnitude of the association** between exposure and outcome (measured by relative risk, odds ratio, etc.). - A stronger association provides more evidence for causality. *Consistency of association* - This **IS** one of Bradford Hill's criteria. - It means the association is observed **repeatedly** across different studies, populations, settings, and times. - Consistent replication strengthens the causal argument. *Specificity of association* - This **IS** one of Bradford Hill's criteria. - It suggests that a specific exposure leads to a specific outcome with limited alternative explanations. - While supportive of causation, Hill noted this criterion is less essential as many exposures have multiple effects.
Question 702: What is the most important criterion in a causal relationship hypothesis?
- A. Temporal association (Correct Answer)
- B. Coherence of association
- C. Specificity of association
- D. Strength of association
Explanation: ***Temporal association*** - This is the **sine qua non** of causality, meaning the exposure or cause must always precede the outcome or effect in time. - Without the exposure occurring before the disease, a causal link cannot be established, even if other criteria are met. *Coherence of association* - This refers to the consistency of findings with current scientific knowledge and **biological plausibility**. - While important for supporting causality, a coherent explanation is not sufficient in itself to prove causation and may even be misleading if current knowledge is incomplete. *Specificity of association* - This criterion suggests that a single exposure should lead to a single outcome, or a single outcome should be caused by a single exposure. - However, many diseases have **multiple causes**, and many exposures can lead to multiple effects, making this a weak criterion in modern epidemiology. *Strength of association* - A **strong association**, often measured by a high relative risk or odds ratio, makes a causal relationship more likely but does not guarantee it. - Strong associations can still be due to **confounding factors** or bias, and weak associations can be causal.
Question 703: What is the primary benefit of screening for diseases?
- A. Early detection of diseases (Correct Answer)
- B. Providing support for patients after diagnosis
- C. Identifying all potential cases of a disease
- D. Timely treatment of identified conditions
Explanation: ***Early detection of diseases*** - This is the **primary benefit** and defining purpose of **screening programs** in public health. - Screening identifies diseases in their **presymptomatic or early stage** when individuals are apparently healthy, allowing for intervention before clinical symptoms appear. - According to epidemiological principles, the goal of screening is to detect disease **earlier than it would be found through routine clinical practice**. - Early detection enables better prognosis through **lead time** and **length time bias** advantages. *Timely treatment of identified conditions* - While treatment is the **ultimate goal** of healthcare, it is not specific to screening—treatment occurs whether disease is found through screening or clinical presentation. - Treatment is the **consequence** of early detection, not the primary benefit of the screening process itself. - The unique value of screening lies in **detection**, not treatment per se. *Providing support for patients after diagnosis* - **Patient support** is an important aspect of healthcare but is not the purpose of screening programs. - This is **post-diagnostic care**, which follows after the screening process has identified cases. *Identifying all potential cases of a disease* - **Screening tests** cannot identify all cases due to inherent limitations in **sensitivity** and **specificity**. - Screening aims to identify a significant proportion of cases in a population, accepting that some will be missed (**false negatives**) and some healthy individuals may test positive (**false positives**).
Question 704: Multiphasic screening means-
- A. Application of two or more screening tests in combination at different geographical areas
- B. Application of separate screening tests for different diseases
- C. Application of two or more screening tests in combination at one time (Correct Answer)
- D. Application of two or more screening tests in combination at different times
Explanation: ***Application of two or more screening tests in combination at one time*** - **Multiphasic screening** involves performing several screening tests simultaneously during a single screening session. - This approach aims to detect multiple diseases or risk factors efficiently within a single visit or examination. *Application of two or more screening tests in combination at different times* - This describes repeated screening or sequential screening, where tests are administered over a period, not the immediate, combined approach of multiphasic screening. - **Multiphasic screening** specifically refers to the concurrent application of multiple tests, not their staggered use. *Application of two or more screening tests in combination at different geographical areas* - This concept relates more to large-scale public health programs or epidemiological studies across regions, rather than the definition of multiphasic screening itself. - Geographical variation is not a defining characteristic of multiphasic screening. *Application of separate screening tests for different diseases* - While multiphasic screening indeed uses separate tests for different diseases, the key aspect is their **simultaneous application** at one time to a single individual, which this option omits. - This option describes the general nature of screening for various conditions but misses the crucial element of combination and timing.
Question 705: What is a key benefit of Randomized Controlled Trials (RCTs) in clinical research?
- A. They can be conducted more quickly than other study types.
- B. They minimize selection bias. (Correct Answer)
- C. They are ideal for studying rare diseases.
- D. They are generally less expensive than other study types.
Explanation: ***They minimize selection bias.*** - **Randomization** in RCTs ensures that participants have an equal chance of being assigned to any of the treatment groups, thereby balancing potential **confounding factors** across groups. - This balance helps to ensure that any observed differences in outcomes between groups are more likely due to the intervention being studied rather than pre-existing differences among participants, thus minimizing **selection bias**. *They can be conducted more quickly than other study types.* - RCTs often require **extensive planning**, recruitment, and follow-up periods, making them one of the **most time-consuming** study designs. - The need for sufficient **power** to detect meaningful differences often translates into longer study durations. *They are ideal for studying rare diseases.* - Due to the requirement for **large sample sizes** to demonstrate statistical significance, RCTs are **not practical** for diseases with low prevalence. - Recruiting enough participants with a rare disease for an RCT can be extremely challenging and often **unfeasible**. *They are generally less expensive than other study types.* - RCTs are typically among the **most expensive** study designs because they involve extensive participant recruitment, intervention administration, data collection, and long-term follow-up. - The costs associated with staff, resources, and monitoring for ethical compliance contribute to their **high financial burden**.
Question 706: Most commonly used blinding technique in epidemiological studies?
- A. None of the options
- B. Single blinding
- C. Double blinding (Correct Answer)
- D. Triple blinding
Explanation: ***Double blinding*** - In **double blinding**, neither the **participants** nor the **researchers** administering the intervention and collecting data know who is in the treatment group versus the control group. - This method is widely used to prevent **observer bias** from the researchers and **participant bias** (e.g., placebo effect) from the subjects, thereby strengthening the study's internal validity. *Single blinding* - In **single blinding**, only the **participants** are unaware of their assignment to either the treatment or control group. - While it helps reduce participant bias, the **researchers' knowledge** of group assignments can still introduce **observer bias**, making it less rigorous than double blinding. *Triple blinding* - **Triple blinding** extends double blinding by ensuring that the **data analysts** are also unaware of the participant group assignments. - This technique further minimizes bias in the **interpretation and analysis of results**, but it is less commonly implemented due to its complexity and increased logistical challenges compared to double blinding. *None of the options* - This option is incorrect because **blinding techniques** are fundamental tools in epidemiological studies and clinical trials to ensure the objectivity and reliability of research findings. - **Blinding** helps eliminate conscious and unconscious biases that could otherwise influence study outcomes.
Question 707: Which one of the following is NOT a utilization rate?
- A. Population bed ratio (Correct Answer)
- B. Bed occupancy rate
- C. Bed turnover ratio
- D. Average length of stay
Explanation: ***Population bed ratio*** - The **population bed ratio** indicates the number of available beds per unit of population, reflecting healthcare **resource availability** rather than resource utilization. - It is a measure of healthcare capacity and access, not how intensively those beds are being used. *Bed occupancy rate* - The **bed occupancy rate** measures the proportion of available hospital beds that are occupied over a given period, directly indicating the **utilization** of bed resources. - A higher rate suggests more efficient use of beds, while a lower rate may indicate underutilization or excess capacity. *Bed turnover ratio* - The **bed turnover ratio** calculates the number of patients discharged per bed over a specific period, reflecting how frequently beds are being used and re-used. - It indicates the **efficiency** with which beds are being utilized and cleared for new patients. *Average length of stay* - The **average length of stay (ALOS)** represents the average number of days a patient remains hospitalized, which directly relates to the **duration of bed utilization** per patient. - A shorter ALOS can indicate more efficient use of beds, while a longer ALOS may suggest higher resource consumption per patient.
Question 708: Which of the following statements is true regarding a combined prospective-retrospective study?
- A. Only prospective follow-up from current time point
- B. Retrospective identification of cohort followed by prospective follow-up (Correct Answer)
- C. Cross-sectional assessment at a single time point
- D. Only retrospective data collection from past records
Explanation: ***Retrospective identification of cohort followed by prospective follow-up*** - This correctly describes a **combined prospective-retrospective study** (also called an **ambispective or historical prospective study**) - The study begins by **retrospectively identifying a cohort** from past records (e.g., employees exposed to a chemical 10 years ago) - **Past exposure data is collected retrospectively** from existing records - The identified cohort is then **followed forward prospectively** from the current time point to observe future outcomes - This approach combines the **efficiency of retrospective data collection** with the **rigor of prospective follow-up** *Only prospective follow-up from current time point* - The word **"only"** is the critical error - it excludes the retrospective component - This describes a **purely prospective cohort study**, not a combined study - A combined study must include **both retrospective and prospective elements** *Only retrospective data collection from past records* - This describes a **purely retrospective study** (case-control or retrospective cohort) - It lacks the prospective follow-up component essential to a combined study *Cross-sectional assessment at a single time point* - This defines a **cross-sectional study** that provides a snapshot at one moment - It involves neither retrospective cohort identification nor prospective follow-up
Question 709: What is the definition of Population Attributable Risk?
- A. The difference between incidence in population and incidence in exposed.
- B. The difference between incidence in population and incidence in non-exposed. (Correct Answer)
- C. The difference between incidence in population and incidence in non-exposed compared with incidence in exposed.
- D. The difference between incidence in exposed and incidence in non-exposed.
Explanation: ***Correct: The difference between incidence in population and incidence in non-exposed.*** - **Population Attributable Risk (PAR)** quantifies the excess incidence of disease in the total population that is attributable to a specific exposure. - Formula: **PAR = Incidence in total population - Incidence in unexposed** - It represents the amount of disease burden that would be eliminated from the entire population if the exposure were completely removed. - PAR accounts for both the strength of association and the prevalence of exposure in the population. *Incorrect: The difference between incidence in population and incidence in exposed.* - This formula (I(population) - I(exposed)) does not correctly capture PAR. - This calculation does not isolate the portion of disease attributable to the exposure across the entire population. - It fails to provide meaningful information about attributable risk. *Incorrect: The difference between incidence in population and incidence in non-exposed compared with incidence in exposed.* - This option introduces unnecessary complexity and is not the standard definition of PAR. - PAR is a simple difference, not a comparative ratio involving exposed individuals. - This description confuses PAR with other epidemiological measures. *Incorrect: The difference between incidence in exposed and incidence in non-exposed.* - This describes **Attributable Risk (AR)** or **Risk Difference (RD)**, not Population Attributable Risk. - Formula: **AR = I(exposed) - I(unexposed)** - AR measures excess risk in the exposed group only, without considering the prevalence of exposure in the total population. - PAR differs from AR by accounting for how common the exposure is in the population.
Question 710: Which study design is most effective for investigating rare adverse effects of a drug?
- A. Cohort study
- B. Cross-sectional study
- C. Case-control study (Correct Answer)
- D. Clinical trial/experimental study
Explanation: ***Case-control study*** - This design starts by identifying individuals with the **rare adverse effect (cases)** and a control group without the effect to look back for exposure to the drug. - It is efficient for studying rare outcomes because it doesn't require following a large population for a long time to observe few events. *Cohort study* - A **cohort study** follows a group of individuals exposed and unexposed to a drug forward in time to observe outcomes. - While good for common outcomes, it would require an **extremely large sample size** and a long follow-up period to observe rare adverse drug effects. *Cross-sectional study* - A **cross-sectional study** assesses exposure and outcome simultaneously at a single point in time. - This design is suitable for determining **prevalence** but cannot establish temporal relationships between drug exposure and rare adverse effects, nor is it efficient for rare outcomes. *Clinical trial/experimental study* - **Clinical trials** are primarily designed to test the efficacy and safety of new interventions, usually focusing on common adverse effects. - They are generally **not powered** or long enough to detect rare adverse events, as such events would occur in very few participants, if any.